Effect of candesartan on progression and regression of retinopathy in type 2 diabetes (DIRECT-Protect 2): a randomised placebo-controlled trial

The Lancet

Volumn 372, Issue 9647, 2008, Pages 1385-1393

  Sjølie, Anne Katrin ^a   Klein, Ronald ^b   Porta, Massimo ^c   Orchard, Trevor ^d   Fuller, John ^e   Parving, Hans Henrik ^f   Bilous, Rudy ^g   Chaturvedi, Nish ^h  

^a ODENSE UNIVERSITY HOSPITAL   (Denmark)

^b UNIVERSITY OF WISCONSIN MADISON   (United States)

^c UNIVERSITY OF TURIN   (Italy)

^d UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^e UNIVERSITY COLLEGE LONDON   (United Kingdom)

^f Mental Health Services CPH   (Denmark)

^g JAMES COOK UNIVERSITY HOSPITAL   (United Kingdom)

^h NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; ANTIDIABETIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; CANDESARTAN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; INSULIN; PLACEBO;

ADULT; AGED; ALBUMIN BLOOD LEVEL; ARTICLE; BLOOD PRESSURE; BLOOD PRESSURE MONITORING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETIC RETINOPATHY; DISEASE COURSE; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRUG EFFECT; DRUG FATALITY; DRUG INDUCED HEADACHE; DRUG WITHDRAWAL; FEMALE; HUMAN; HYPERTENSION; INFLUENZA; LIMB PAIN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; PARALLEL DESIGN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REMISSION; TREATMENT OUTCOME;

EID: 53749108177     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(08)61411-7     Document Type: Article

References (48)

1. WHO. Diabetes fact sheet number 312. Geneva, Switzerland, World Health September 2006. http://www.who.int/mediacentre/factsheets/fs312/en/ (accessed July 23, 2008).
2. Aiello L.P., Gardner T.W., King G.L., et al. Diabetic retinopathy. Diabetes Care 21 (1998) 143-156
3. Stratton I.M., Kohner E.M., Aldington S.J., et al. UKPDS 50: Risk factors for incidence and progression of retinopathy in type II diabetes over 6 years from diagnosis. Diabetologia 44 (2001) 156-163
4. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352 (1998) 837-853
5. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 317 (1998) 703-713
6. Schrier R.W., Estacio R.O., Esler A., and Mehler P. Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and strokes. Kidney Int 61 (2002) 1086-1097
7. Grant R.W., Buse J.B., Meigs J.B., and University HealthSystem Consortium (UHC) Diabetes Benchmarking Project Team. Quality of diabetes care in U.S. academic medical centers. Low rates of medical regimen change. Diabetes Care 28 (2005) 337-442
8. Prévost G., Phan T.M., Mounier-Vehier C., and Fontaine P. Control of cardiovascular risk factors in patients with type 2 diabetes and hypertension in a French national study (Phenomen). Diabetes Metab 31 (2005) 479-485
9. Zhang L.Y., Krzentowski G., Albert A., and Lefevbre P.J. Risk of developing retinopathy in Diabetes Control and Complications Trial type 1 diabetic patients with good or poor metabolic control. Diabetes Care 24 (2001) 1275-1279
10. Photocoagulation treatment of proliferative diabetic retinopathy: the second report of diabetic retinopathy study findings. Ophthalmology 85 (1978) 82-106
11. Early photocoagulation for diabetic retinopathy, ETDRS report number 9. Early Treatment Diabetic Retinopathy Study Research Group. Ophthalmology 98 (1991) 766-785
12. Heart Outcomes Prevention Evaluation Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 355 (2000) 253-259
13. Parving H.H., Lehnert H., Brochner-Mortensen J., Gomis R., Andersen S., and Arner P. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 345 (2001) 870-878
14. Brenner B.M., Cooper M.E., de Zeeuw D., et al., RENAAL Study Investigators. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345 (2001) 861-869
15. Lewis E.J., Hunsicker L.G., Clarke W.R., et al., Collaborative Study Group. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 345 (2001) 851-860
16. Patel A., and ADVANCE Collaborative Group. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet 370 (2007) 829-840
17. Parving H.H., Persson F., Lewis J.B., Lewis E.J., Hollenberg N.K., and AVOID Study Investigators. Aliskiren combined with losartan in type 2 diabetes and nephropathy. N Engl J Med 358 (2008) 2433-2446
18. Strippoli G.F., Bonifati C., Craig M., Navaneethan S.D., and Craig J.C. Angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists for preventing the progression of diabetic kidney disease. Cochrane Database Syst Rev 4 (2006) CD006257.
19. Ruggenenti P., Fassi A., Ilieva A.P., et al., Bergamo Nephrologic Diabetes Complications Trial (BENEDICT) Investigators. Preventing microalbuminuria in type 2 diabetes. N Engl J Med 351 (2004) 1941-1951
20. The DIRECT Programme Study Group. The DIabetic REtinopathy Candesartan Trials (DIRECT) Programme, rationale and study design. J Renin Angiotensin Aldosterone Syst 3 (2002) 255-261
21. The DIRECT Programme Study Group. The DIabetic REtinopathy Candesartan Trials (DIRECT) Programme: baseline characteristics. J Renin Angiotensin Aldosterone Syst 6 (2005) 25-32
22. Early Treatment Diabetic Retinopathy Study Research Group. Grading diabetic retinopathy from stereoscopic color fundus photographs-an extension of the modified Airlie House classification. ETDRS report number 10. Ophthalmology 98 (1991) 786-806
23. Early Treatment Diabetic Retinopathy Study Research Group. Fundus photographic risk factors for progression of diabetic retinopathy. ETDRS report number 12. Ophthalmology 98 (1991) 823-833
24. Sun J., Zhao Q., and Zhao X. Generalised log-rank tests for interval-censored failure time data. Scand J Stat 32 (2005) 49-57
25. Wellner J.A., and Zhan Y. A hybrid algorithm for computation of the NPMLE from censored data. J Am Stat Assoc 92 (1997) 945-959
26. Alioum A., and Commenges D. A proportional hazards model for arbitrarily censored and truncated data. Biometrics 52 (1996) 512-524
27. O'Brien RG, Castelloe J. Exploiting the link between the Wilcoxon-Mann-Whitney test and a simple odds statistic. Proceedings of the Thirty-first Annual SAS Users Group International Conference. Cary, NC, USA: SAS Institute, USA. http://www2.sas.com/proceedings/sugi31/209-31.pdf (accessed Jan 27, 2008).
28. Matthews D.R., Stratton I.M., Aldington S.J., Holman R.R., Kohner E.M., and UK Prospective Diabetes Study Group. Risks of progression of retinopathy and vision loss related to tight blood pressure control in type 2 diabetes mellitus: UKPDS 69. Arch Ophthalmol 122 (2004) 1631-1640
29. Svensson P., de Faire U., Sleight P., Yusuf S., and Ostergren J. Comparative effects of ramipril on ambulatory and office blood pressures: a HOPE Substudy. Hypertension 38 (2001) 28-32
30. Cuspidi C., Muiesan M.L., Valagussa L., et al., CATCH investigators. Comparative effects of candesartan and enalapril on left ventricular hypertrophy in patients with essential hypertension: the candesartan assessment in the treatment of cardiac hypertrophy (CATCH) study. J Hypertens 20 (2002) 2293-2300
31. Ariff B., Zambanini A., Vamadeva S., et al. Candesartan- and atenolol-based treatments induce different patterns of carotid artery and left ventricular remodeling in hypertension. Stroke 37 (2006) 2381-2384
32. Henricsson M., Nilsson A., Heijl A., Janzon L., and Groop L. Mortality in diabetic patients participating in an ophthalmological control and screening programme. Diabet Med 14 (1997) 576-583
33. Klein R., Klein B.E., Moss S.E., and Cruickshanks K.J. Association of ocular disease and mortality in a diabetic population. Arch Ophthalmol 117 (1999) 1487-1495
34. Rajala U., Koskela P., Pajumppaa H., and Keinanen-Kiukaannieemi S. High cardiovascular disease mortality in subjects with visual impairment caused by diabetic retinopathy. Diabetes Care 23 (2000) 957-961
35. Sundell J., Janatuinen T., Ronnemaaa T., et al. Diabetic background retinopathy is associated with impaired coronary vasoreactivity on people with type 1 diabetes. Diabetologia 47 (2004) 725-731
36. Ohno T., Takamoto S., Motomura N., et al. Coronary artery by-pass grafting versus coronary implantation of sirolimus-eluting stents in patients with diabetic retinopathy. Ann Thorax Surg 84 (2007) 1474-1478
37. Ohno T., Takamoto S., and Motomura N. Diabetic retinopathy and coronary artery disease from the cardiac surgeon's perspective. Ann Thorax Surg 85 (2008) 681-689
38. Deinum J., Derkx F.H., Danser A.H., and Schalekamp M.A. Identification and quantification of renin and prorenin in the bovine eye. Endocrinology 126 (1990) 1673-1682
39. Sarlos S., and Wilkinson-Berka J.L. The renin-angiotensin system and the developing retinal vasculature. Invest Ophthalmol Vis Sci 46 (2005) 1069-1077
40. Funatsu H., Yamashita H., Nakanishi Y., and Hori S. Angiotensin II and vascular endothelial growth factor in the vitreous fluid of patients with proliferative diabetic retinopathy. Br J Ophthalmol 86 (2002) 311-315
41. Aiello L.P., Avery R.L., Arrigg P.G., et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med 331 (1994) 1480-1487
42. Gardner T.W., Antonetti D.A., Barber A.J., LaNoue K.F., and Levison S.W. Diabetic retinopathy: more than meets the eye. Surv Ophthalmol 47 (2002) 253-262
43. Moravski C.J., Kelly D.J., Cooper M.E., et al. Retinal neovascularization is prevented by blockade of the renin-angiotensin system. Hypertension 36 (2000) 1099-1104
44. Knudsen S.T., Bek T., Poulsen P.L., Hove M.N., Rehling M., and Mogensen C.E. Effects of losartan on diabetic maculopathy in type 2 diabetic patients: a randomized, double-masked study. J Intern Med 254 (2003) 147-158
45. Nagisa Y., Shintani A., and Nakagawa S. The angiotensin II receptor antagonist candesartan cilexetil (TCV-116) ameliorates retinal disorders in rats. Diabetologia 44 (2001) 883-888
46. Nakamura H., Inoue T., Arakawa N., et al. Pharmacological and pharmacokinetic study of olmesartan medoxomil in animal diabetic retinopathy models. Eur J Pharmacol 512 (2005) 239-246
47. Belcher G., Hübner R., George M., Elmfeldt D., and Lunde H. Candesartan cilexetil: safety and tolerability in healthy volunteers and patients with hypertension. J Hum Hypertens 11 (1997) 85-89
48. Julius S., Nesbitt S.D., Egan B.M., et al. Trial of Preventing Hypertension (TROPHY) Study Investigators. Feasibility of treating prehypertension with an angiotensin-receptor blocker. N Engl J Med 354 (2006) 1685-1697